Which country is venetoclax/venetoclax produced in?

Venetoclax/Venetoclax is a drug used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or acute myeloid leukemia (AML) in adults. Its trade names are Venclexta and Venclyxto. This drug is developed and produced by AbbVie Biopharmaceutical Company (AbbVie) and sold by AbbVie and Genentech. It is the first BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) and can be used in combination with other drugs, including azacitidine, decitabine, etc.

Veneclat works by binding to a protein calledBcl-2, which is highly expressed in cancer cells of chronic lymphocytic leukemia. The Bcl-2 protein helps cancer cells survive longer in the body and increases their resistance to anti-cancer drugs. Venetoclax attaches to Bcl-2 and blocks its function, causing cancer cells to die and slowing the progression of the disease. It can rapidly and effectively induce apoptosis in CLL cells, potentially starting to take effect within 24 hours and triggering tumor lysis syndrome.

The most common side effects of this drug include decreased levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (a decrease in red blood cell count), nose and throat infections, and fatigue. Although venetoclax has been shown to be highly effective in treating these conditions, patients need to be closely monitored for these side effects during use and take appropriate measures to manage them if necessary.